Phase II study of amrubicin monotherapy for treating elderly and poor-risk patients with small-cell lung cancer.

Trial Profile

Phase II study of amrubicin monotherapy for treating elderly and poor-risk patients with small-cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Amrubicin (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2016 Status changed from recruiting to completed.
    • 06 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top